Cost-Efficiency and Speed: The Twin Benefits of High Throughput Screening
Academic institutions are increasingly adopting High Throughput Screening (HTS) technologies to advance basic research and support translational medicine. Universities and research labs are vital contributors to HTS innovation.
The High Throughput Screening Market is expected to achieve USD 44.69 billion by 2032, growing at a CAGR of 7.80% between 2023 and 2032. Academic research plays a pivotal role in this expansion.
HTS enables scientists in universities to screen small molecules, peptides, and genetic materials to better understand disease mechanisms. It also supports the validation of druggable targets before clinical trials.
Collaborations between academia and biopharma companies are boosting funding and technology transfer. Academic discoveries are frequently licensed to industry partners, fueling commercialization of new therapies.
This trend ensures that HTS is not confined to large pharmaceutical labs but is increasingly accessible to researchers worldwide.
👉 Learn more about the High Throughput Screening Market.